Jazz Reports Continued Adoption of Xywav for Narcolepsy and IH
Jazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Tag: Jazz Pharmaceuticals
All
Latest
All
Latest
Axsome Therapeutics to Acquire Sunosi from Jazz Pharmaceuticals
The acquisition of Sunosi adds a high-potential commercial asset to Axsome’s late-stage neuroscience portfolio.
All
Latest
Taking Back Control in Hypersomnia Disorders
A common concern in narcolepsy and idiopathic hypersomnia is a feeling of having little control over symptoms, which can lead to despair. But disorders of excessive sleepiness do have both medication and non-medication treatment approaches.
Onera New Series B Funding to Facilitate Commercialization of Home Sleep Test Patch
The funding will allow for larger scale clinical studies, expanding partnerships in the EU and US, and expedited product development.
Read More
FDA Grants Orphan Drug Status to Xywav, Citing “Greatly Reduced Chronic Sodium Burden Compared to Xyrem”
The FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness associated with narcolepsy.
Read MoreJazz Pharmaceuticals Shares Results from Sleep Medicine Research & Therapy Development
Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read More
Jazz Pharmaceuticals Presents Phase 3 Results of Xywav in Idiopathic Hypersomnia
The AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read More2020 Roundup: The Year in FDA Clearances & Approvals for Sleep Medicine
It’s been an unusual year. But, mostly as usual, the US Food & Drug Administration continued to review device and drug applications across all fields of medicine.
Read More
What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk
A literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read More
Xywav Phase 3 Data Published in SLEEP
Results of the double-blind, placebo-controlled, randomized-withdrawal, multicenter study were previously presented at World Sleep 2019.
Read More
FDA Fast Tracks Xywav for Idiopathic Hypersomnia
“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”
Read More
Bookmark This American Heart Association Webpage for Cardio-Sleep Education
With financial support from Jazz Pharmaceuticals, the American Heart Association will create sleep-related educational multimedia content.
Read More
Xywav or Xyrem: What’s the Difference?
The FDA approved a new oxybate formulation for excessive daytime sleepiness or cataplexy in narcolepsy. Should your patients switch?
Read MoreJazz Presents New Data on Xywav & Sunosi at Virtual SLEEP 2020
Highlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read More
FDA Approves Low Sodium Narcolepsy Oral Solution
Marketed by Jazz Pharmaceuticals, Xywav is for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read More
7 Myths About Narcolepsy, Debunked
Sleep professionals and the general public have misperceptions about the neurological sleep disorder. How many did you believe?
Read MoreThese Sleep Medicine Products Got FDA Nod in 2019
Sleep Review annually rounds up the sleep medicine devices, pharmaceuticals, and more that earned US Food and Drug Administration clearance.
Read More
FDA Accepts NDA for Low-Sodium Alternative to Xyrem for Narcolepsy
The FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc’s NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read More